Ph III Adjuvant Melanoma Monotherapy
Research payments
$398,089
Through program year 2022, $398,089 in research payments was reported against Ph III Adjuvant Melanoma Monotherapy, across 28 payments, paid by E.R. Squibb & Sons, L.L.C..
- Paid by
- E.R. Squibb & Sons, L.L.C.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2022 | Research | $397,501 | 26 |
| 2021 | Research | $588 | 2 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Neil Belman Bethlehem, PA Named on 2 payments
- Leslie Fecher Ann Arbor, MI Named on 2 payments
- Karl Lewis Aurora, CO Named on 2 payments
- Ragini Kudchadkar Avondale Estates, GA Named on 2 payments
- Patrick Ott Boston, MA Named on 2 payments
- Nikhil Khushalani Tampa, FL Named on 1 payment
- Charles Cowey Dallas, TX Named on 1 payment
- Thomas Amatruda Fridley, MN Named on 1 payment
- George Ansstas Saint Louis, MO Named on 1 payment
- David Spigel Nashville, TN Named on 1 payment
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.